International Clinical Trial: A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer

Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07890597) titled 'A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer' on Oct. 16.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Pfizer

Condition: Early Breast Cancer Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)

Intervention: Drug: Atirmociclib Drug: giredestrant

Recruitment Status: Not recruiting ...